Xu Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xu Feng has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Liqin Jia
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China
2 shared publicationsQianlan Yao
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China
2 shared publicationsYuyin Xu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China
2 shared publicationsChengli Yu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China
1 shared publication- Cunjian Yi
Department of Clinical Medical Research Center for Personalized Diagnosis and Treatment of Cancer, The First Affiliated Hospital of Yangtze University, Jingzhou First People’s Hospital, Jingzhou, Hubei, China
1 shared publication D. Cao
Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, No.37 of Wainan Guoxue Lane, Chengdu, Sichuan Province, China
1 shared publication
Latest Publications
- 15 August 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 274, 156177
CDKN2A alternations in non-small cell lung cancer: An evaluation using next-generation sequencing
- 15 August 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 274, 156177
CDKN2A alternations in non-small cell lung cancer: An evaluation using next-generation sequencing
- Open Access
- 7 August 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (10) , 1780-1791
Approaches for Lynch syndrome screening and characteristics of subtypes with mismatch repair deficiency in patients with colorectal carcinoma
To evaluate different Lynch syndrome (LS) screening approaches and establish an efficient and sensitive strategy are critical for clinical practice. In total, 583 patients with colorectal carcinoma (CRC) at Fudan University Shanghai Cancer Center were enrolled. Patient samples were examined by immunohistochemistry (IHC) and next‐generation sequencing (NGS), and MLH1 promoter hypermethylation (MPH) was detected in MLH1‐deficient cases. Germline genetic testing was performed in cases with deleterious variants and large genomic rearrangements (LGRs) of tumor MMR genes were detected in cases with dMMR or MSI‐H cases with no MMR germline variants. Our results showed that triage with IHC and followed by BRAF/MLH1 methylation testing (Strategy 1) identified 93.3% (70/75) of LS cases. IHC followed by germline NGS (Strategy 2) or direct tumor NGS (Strategy 3) both identified 98.7% (74/75) of LS cases. The proportion of LGRs in LS cases was 16.0% (12/75), while 84.0% (63/75) showed SNV/Indel. The average cost per patient was ¥6010.81, ¥6058.48, and ¥8029.98 for Strategy 1, Strategy 2 and Strategy 3, respectively. The average time spent on different strategies was 4.74 days (Strategy 1), 4.89 days (Strategy 2), and 14.50 days (Strategy 3) per patient, respectively. LS and Lynch‐like syndrome (LLS) were associated with an earlier onset age than MPH. In conclusion, we compared different workflows for LS screening and IHC plus germline NGS is recommended for LS screening when taking sensitivity, time, and cost into account. Moreover, multiplex ligation‐dependent probe amplification made up for the shortcoming of NGS and should be incorporated into routine screening.
- 7 August 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (10) , 1780-1791
Open AccessApproaches for Lynch syndrome screening and characteristics of subtypes with mismatch repair deficiency in patients with colorectal carcinoma
To evaluate different Lynch syndrome (LS) screening approaches and establish an efficient and sensitive strategy are critical for clinical practice. In total, 583 patients with colorectal carcinoma (CRC) at Fudan University Shanghai Cancer Center were enrolled. Patient samples were examined by immunohistochemistry (IHC) and next‐generation sequencing (NGS), and MLH1 promoter hypermethylation (MPH) was detected in MLH1‐deficient cases. Germline genetic testing was performed in cases with deleterious variants and large genomic rearrangements (LGRs) of tumor MMR genes were detected in cases with dMMR or MSI‐H cases with no MMR germline variants. Our results showed that triage with IHC and followed by BRAF/MLH1 methylation testing (Strategy 1) identified 93.3% (70/75) of LS cases. IHC followed by germline NGS (Strategy 2) or direct tumor NGS (Strategy 3) both identified 98.7% (74/75) of LS cases. The proportion of LGRs in LS cases was 16.0% (12/75), while 84.0% (63/75) showed SNV/Indel. The average cost per patient was ¥6010.81, ¥6058.48, and ¥8029.98 for Strategy 1, Strategy 2 and Strategy 3, respectively. The average time spent on different strategies was 4.74 days (Strategy 1), 4.89 days (Strategy 2), and 14.50 days (Strategy 3) per patient, respectively. LS and Lynch‐like syndrome (LLS) were associated with an earlier onset age than MPH. In conclusion, we compared different workflows for LS screening and IHC plus germline NGS is recommended for LS screening when taking sensitivity, time, and cost into account. Moreover, multiplex ligation‐dependent probe amplification made up for the shortcoming of NGS and should be incorporated into routine screening.
- Open Access
- 20 September 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 631, 86-92
ASS1 regulates immune microenvironment via CXCL8 signaling in ovarian cancer
- 20 September 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 631, 86-92
Open AccessASS1 regulates immune microenvironment via CXCL8 signaling in ovarian cancer
- 1 August 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (8) , 1082-1088
Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial
- 1 August 2015
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 41 (8) , 1082-1088
Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial